# Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

> **NCT01570036** · PHASE2 · COMPLETED · sponsor: **George E. Peoples** · enrollment: 275 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Herceptin
- **DRUG:** NeuVax vaccine
- **DRUG:** GM-CSF

## Key facts

- **NCT ID:** NCT01570036
- **Lead sponsor:** George E. Peoples
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-21
- **Primary completion:** 2018-09-28
- **Final completion:** 2018-09-28
- **Target enrollment:** 275 (ACTUAL)
- **Last updated:** 2020-12-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01570036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01570036, "Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01570036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*